Skip to main content

Advertisement

Table 4 Main and secondary outcomes for website groups at six week follow up

From: Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website

Variable Website Website + support No website group Significance
IBS-SSS total mean (n = 123) 197.0 (172.4 - 221.7) 208.0 (188.1 - 233.0) 162.8 (137.4 -188.3) p = 0.037*
IBS-QOL score (n = 123) 71.6 (67.9-75.2) 67.6 (63.9-71.3) 69.4 (65.7-73.1) p = 0.315
HADS score for anxiety (n = 114) 8.9 (7.9-9.8) 9.7 (8.8-10.6) 8.3 (7.3-9.2) p = 0.109
HADS score for depression (n = 114) (%)     p = 0.122
Normal (0–7) 35 (89.7) 28 (71.8) 31 (79.5)  
Mild (8–10) 2 (5.1) 8 (20.5) 8 (20.5)  
Moderate or Severe (11–21) 2 (5.1) 3 (7.7) 0 (0)  
Enablement score (n = 113) (%)     p = 0.000**
0 7 (18.4) 4 (10.5) 21 (56.8)  
1-2 7 (18.4) 5 (13.2) 4 (10.8)  
3-5 13 (34.2) 15 (39.5) 7 (18.9)  
6-12 11 (28.9) 14 (36.8) 5 (13.5)  
  1. Analysis of the 6 week follow-up scores.
  2. ANCOVA for IBS SSS, IBS-QOL and HADs Anxiety, Mean (95% CI). Ordinal Regression for HADs Depression and Enablement (n (%).